The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation. (1st June 2018)

• Record Type: Journal Article
• Authors: Faraoni, Isabella; Aloisio, Francesca; De Gabrieli, Antonio; Consalvo, Maria Irno; Lavorgna, Serena; Voso, Maria Teresa; Lo-Coco, Francesco; Graziani, Grazia
• Is Part Of: Cancer letters. Volume 423(2018)
• Page Start: 127
• Page End: 138
• Publication Date: 2018-06-01
• Subjects: PARP1 -- Lynparza -- AML -- FAS -- TRAIL receptors; BRCA1 DNA repair associated -- BRCA2 DNA repair associated -- DR4 TNF receptor superfamily member 10a (TNFRSF10A) -- DR5 TNF receptor superfamily member 10b (TNFRSF10B) -- DSBs DNA double strand breaks -- FAS Fas cell surface death receptor -- FASL FAS Ligand -- FLT3 fms-related tyrosine kinase -- FLT3LG FLT3 ligand -- GAPDH glyceraldehyde-3-phosphate dehydrogenase -- HR homologous recombination -- IκBα NFKB inhibitor alpha (NFKBIA) -- NF-κB nuclear factor kappa B subunit 1 -- NPM1 nucleophosmin1, (nucleolar phosphoprotein B23, numatrin) -- PAR poly(ADP-ribose) -- PARP1 poly(ADP-ribose) polymerase 1 -- PARP2 poly(ADP-ribose) polymerase 2 -- PARPi PARP inhibitors -- PARylation poly(ADP-ribosyl)ation -- SCF stem cell factor, (KIT ligand) -- SSBs single strand breaks -- TRAIL TNF-related apoptosis-inducing ligand; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2018.03.008
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Olaparib is a potent orally bioavailable poly(ADP-ribose) polymerase inhibitor (PARPi), approved for BRCA-mutated ovarian and breast cancers. We recently showed that olaparib at clinically achievable concentrations exerts anti-proliferative and pro-apoptotic effects in vitro as monotherapy against primary acute myeloid leukemia (AML) blasts, while sparing normal bone marrow (BM) hematopoietic cells. Since AML expresses low levels of death receptors that may contribute to apoptosis resistance, in this study we investigated whether the anti-leukemia activity of olaparib involves modulation of FAS and TRAIL receptors DR5 and DR4. Our data show that the primary AML samples tested express FAS and DR5 transcripts at levels lower than normal BM. In this context, apoptosis triggered by olaparib is associated with a dose-dependent up-regulation of death receptors expression and caspase 8 activation. Olaparib-mediated FAS up-regulation requires NF-κB activation, as indicated by the increase of p65 phosphorylation and decrease of IκBα. Moreover, FAS up-regulation is abrogated by pretreatment of AML cells with two different NF-κB inhibitors. These results indicate that NF-κB activation and consequent induction of death receptor expression contribute to the anti-leukemia effect of olaparib in AML. Highlights: A new mechanism involved in the anti-AML activity of the PARPi olaparib is proposed. Olaparib induces up-regulation of death receptors in proliferating or resting myeloid blasts. PARPi-induced up-regulation of death receptors requires NF-κB activation. Olaparib monotherapy represents an attractive treatment option for relapsed/refractory AML.